50 results about "Ginsenoside rg2" patented technology

The invention discloses a ginsenoside-containing medicine composition. The ginsenoside-containing medicine composition comprises the following active ingredients by weight percent: 20-70 percent of ginsenoside Rg, 10-40 percent of ginsenoside Rh2 and 20-50 percent of notoginsenoside ft1. The invention also provides application of the composition to drugs for preventing and treating cancers, auxiliary anti-cancer drugs and medicines or health products used for strengthening the organic immunity. The ginsenoside-containing medicine composition can effectively inhibit tumor cells and stimulate lymphocyte proliferation, has excellent pharmacological effects, and has better security on the basis of saving resources and taking better drug effects.

Medicinal composition containing ginseng secondary glycosides, its preparation method and application. The present composition contains mainly, as active ingredients, the ginsenoside with protopanoxadiol as aglucone (ginsenoside Rg3) and the ginsenoside with protopanoxatriol as aglucone (ginsenoside Rg2 and ginsenoside Rh1). It is prepared from the ginseng genus of plants through extracting, acid hydrolyzing and using macroreticular resin to separate, purify and concentrate. It is useful in the manufacture of medicaments for treating CHD, angina pectoris, myocardial ischemia, hemorrhagic shock, heart failure, and arrhythmia.

The present invention relates to kind one ginsenoside Rg2 preparing process suitable for industrial production, and gradient salt separation process with simple operation is used in substituting traditional silicon gel chromatography process. The present invention also relates to medicine composition with ginsenoside Rg2 as active component and its application in medicine for preventing and treating dementia, depression, peripheral circulation disturbance and related diseases.

The present invention discloses an inclusion complex containing the panaxsaponin Rg2 and the preparation method. The inclusion complex of the invention consists of the panaxsaponin Rg2 and the hydroxypropyl-Beta-cyclodextrin. The preparation method of the present invention is as following. The hydroxypropyl-Beta-cyclodextrin water solution is prepared; the hydroxypropyl-Beta-cyclodextrin solution is kept in the water bath; the extraction powder of the panaxsaponin Rg2 or the extraction of the liquid-typed Rg2 dissoluted by the solvent is added before mixing and complex; therefore the liquid inclusion complex is obtained and the inclusion complex after drying. The inclusion complex of the present invention has functions of increasing the heart perfusion and the blood flow, expanding the diameter of the vein and the artery, improving the microcirculation disturbance, improving the myocardial ischemia and anti-thrombosis effect. The present invention can significantly reduce the acute toxicity of the panaxsaponin Rg2.

The present invention relates to a processing method for preparing pharmacologically potent ginseng product and the extract therefrom which could provide abundant amount ginsenoside Rg5 showing various pharmacological activities with applying selected range of pressure and temperature into the method and therefore the composition comprising the processed ginseng and the extract thereof can be useful as a medicament or health care food in the prevention or treatment of various diseases, especially, cancer disease.

The present invention discloses a new medical use of ginsenoside Rh1, and specifically relates to an application of ginsenoside Rh1 in preparation of drugs for improving glucocorticoid resistance. According to the present invention, in vitro and in vivo study results show that: with the ginsenoside Rh1, hormone resistance caused by long term and high dose use of dexamethasone can be significantly improved so as to improve the anti-inflammatory effect of dexamethasone, the action is related to up-regulation of the glucocorticoid receptor, and blood sugar increase can not be caused, such that the application prospects for preparation of the drugs for improving glucocorticoid resistance are provided.

The invention relates to a panaxatriol saponin composition, wherein active components with immune-enhancing function in the composition mainly comprise ginsenoside-Re, ginsenoside-Rg1, ginsenoside-Rg2 and ginsenoside-Rh1, and the components in percentage by weight are: 25 to 50 percent of the ginsenoside-Re, 15 to 50 percent of the ginsenoside-Rg1, 0 to 30 percent of the ginsenoside-Rg2, and 0 to 30 percent of the ginsenoside-Rh1. The panaxatriol saponin composition of the proportions has the immune-enhancing activity far larger than that of a ginseng monomer saponin, improves the curative effect of the immune-enhancing function, and reduces the toxic side effects. In addition, the preparation method is simple, and the production cost is low.

The invention relates to the technical field of medical treatment, in particular to application of ginsenoside CK in the preparation of external drugs and health cosmetics to treat atopic dermatitis.OVA-sensitized (ovalbumin-sensitized) atopic dermatitis mouse models are established; filaggrin gene-deficient atopic dermatitis mice are selected; the two types of mice are fed with ginsenoside CK with different concentrations. The results show that ginsenoside CK can evidently reduce the scratching frequency of the OVA- sensitized AD (atopic dermatitis) model mice and reduce epidermal and dermalthickness of the mice; the therapeutic effect of a medium concentration group and that of the high concentration group are evidently higher than that of the low concentration group and that of a dexamethasone cream group; ginsenoside CK can reduce dermatitis score and scratching frequency of Ft mice and the expression of IL-4 at skin lesions of the Ft mice, the therapeutic effect of the medium concentration group is higher than that of the low concentration group and that of the high concentration group, and dexamethasone cream cannot improve atopic dermatitis type skin lesions with skin barrier dysfunction caused by filaggrin gene deficiency. The external drugs and health cosmetics made with ginsenoside CK herein have the advantages of good therapeutic effect and good safety.

The invention discloses a rhizopus stolonifer capable of biologically converting ginsenosides. A fermentation product is analyzed by an HPLC (High Performance Liquid Chromatography) system to prepare a component with a reduced color spectrum peak value in an original panaxatriol saponins and a component with an increased peak value in the panaxatriol saponins fermentation product thereof. By isolation and identification, a converted substance in the panaxatriol saponins is confirmed to be ginsenosides Re, a compound (1) in the panaxatriol saponins fermentation product is confirmed to be ginsenosides Rh1, a compound (2) is confirmed to be ginsenosides Rg3, and a compound (3) is confirmed to be ginsenosides Rg2. By speculation, the ginsenosides Re in the panaxatriol saponins is converted into the ginsenosides Rh1 by the black rhizopus or the ginsenosides Re is firstly converted into the ginsenosides Rg2 and then converted into ginsenosides Rh1, and the detailed conversion path is to be further researched.

The invention relates to a semi-synthetic method of pseudo-ginsenoside F11. The method adopts ginsenoside Rg2 as raw material and synthesizes the pseudo-ginsenoside F11 compound by the steps of oxidation and cyclization and the like under acid condition; and the chemical name thereof is 6-O-Alpha-L-rhamnopyranosyl(1-2)-Beta-D-glucopyranosyl-dammar-20S, 24S-epoxy-3Beta, 6Alpha, 12Beta, 25-tetrahydric alcohol. The method has convenient source of materials, mild reaction condition, simple and convenient operation, high yield and short production period and is suitable for realizing industrial production.

The invention discloses an application of ginsenoside Rg1, Rh1 and Ppt to the resistance of cognitive competence and study memory function disorders, in particular relates to an application of ginsenoside Rg1 and / or metabolites thereof, such as Rh1 and / or Ppt to the preparation of medicines and health products preventing, relieving and / or curing diseases or symptoms capable of causing the cognitive competence disorders and / or the study memory function disorders, particularly the Alzheimer's disease (AD). The invention is applied to the preparation of the medicines and the health products improving the cognitive competence and the study memory function.

The present invention provides a method of extracting ginsenoside Rg2, which is applied to mass production. The method of the present invention employs gradient salting-out instead of conventional silica gel chromatography, and therefore enables convenient performance and mass production of ginsenoside Rg2. Provided are also a pharmaceutical composition comprising ginsenoside Rg2 as an active ingredient, and prophylactic and therapeutic agents for preventing and treating dementia, depression, peripheral circulation disorder and related diseases, utilizing the pharmaceutical composition.

The invention relates to application of ginsenoside Rg1 to preparation of medicines for prevention and / or treatment of myocardial ischemia. The ginsenoside Rg1 is capable of improving myocardial energy metabolism and cardiac functions, reducing myocardial infarction area and increasing cardiac surface blood flow volume to realize treatment and prevention of myocardial ischemia.

The inventoin provides a use of ginsenoside F2 in the prevention, improvement or treatment of liver disease, and a pharmaceutical composition, a health functional food, and a feed composition including ginsenoside F2. Ginsenoside F2 inhibits fat synthesis and accumulation in the liver, and increases distribution of regulatory T cells capable of inhibiting activity of inflammatory cells, thereby preventing hepatitis, and also increases expression of anti-inflammatory cytokine IL-10 in regulatory T cells, and inhibits differentiation of naive T cells into Th17 cells, and is thereby effectively used for the treatment of various liver diseases.

The invention discloses use of ginsenoside Rg2 in preparing a medicine for treating myelosuppression and a medicine containing the ginsenoside Rg2, and belongs to the technical field of medicines. The invention provides novel use of the ginsenoside Rg2 in resisting myelosuppression. When myelosuppression is caused by chemotherapy, the ginsenoside Rg2 can promote bone marrow cell component recovery, increases the bone marrow nucleated cell number, remarkably improves the number of bone marrow granulocyte-mononuclear and pre-B colony forming units, promotes proliferation of granulocyte-mononuclear and pre-B hematopoietic progenitor cells, and thus has an effect of promoting bone marrow hematopoiesis.

Beneficial effects are obtained by topically applying ginsenoside F2 to the skin to improve skin conditions, improve water content on the skin surface and related benefits improving skin problems associated with acne or atopy, providing a skin whitening effect, helping control of sebaceous secretion, tightening skin pores, or improving skin complexion through enhanced blood circulation, but also to improve scalp and hair conditions, such as providing an anti-dandruff effect, promoting hair growth, or preventing generation of grey hair.

The invention discloses a preparation method of a novel ginsenoside--dihydro ginsenoside Rg2, which has more than 80 percent of yield and is suitable for industrial production. The dihydro ginsenoside Rg2 has the functions of preventing or treating diseases related to microcirculatory disturbance.

The present invention relates to a semisynthesis method of 20(s)-ginsenoside Rgz. It includes the following steps: dissolving the raw material ginsenoside Re in 20-30% ethyl alcohol aqueous solution with 0.01-0.05 MHCl, heating for 2-3 hr, in water bach with 70-80 deg.c, cooling, making said solution pass through anion exchange resin, removing acid and collecting effluent, recovering solvent to obtain ginsenoside Rgz crude product, then using methyl alcohol-ethyl acetate to make said crude product be repeatedly recrystallized to make purification or making said crude product undergo the process of silica-gel column chromatographic treatment and using chloroform-methyl alcohol-water as eluent, collecting ginsenoside Rg2 portion.

The invention belongs to the field of medicine or natural medicine chemistry, and particularly relates to application of a natural product-ginsenoside Rb3 in preparing a medicine for treating depressive disorder. In the application, ginsenoside Rb3 is directly extracted and obtained from panax notoginseng, ginseng or American ginseng; the dosage is 3.0-20.0mg per kilo of weight each day. Through organically regulating in vivo neurotransmitter and neural network balance and actions of multiple ways and multiple targets such as promoting nerve growth and the like, ginsenoside Rb3 is applied in preparing medicine for treating depressive disorder, so that obvious anti-depression effect is obtained. In addition, ginsenoside Rb3 can be extracted and obtained through traditional Chinese medicine or natural plants, and can be supplied for patients with depressive disorder to be continuously taken for a long period. The ginsenoside Rb3 has clear effective substance, obvious therapeutic effect, small toxic or side effect and definite action mechanism, and is in favor of radically treating depressive disorder and avoiding recurrence of depressive disorder.

The invention provides a biological fermentation composition with an anti-cancer effect as well as a preparation method and application thereof, and belongs to the technical field of biological engineering. The biological fermentation composition with the anticancer effect is prepared from the following raw materials in parts by weight: 50 to 100 parts of selenium-enriched natto fermentation extract, 2 to 5 parts of ginsenoside Rg2, 1 to 3 parts of ginsenoside Rg3, 2 to 5 parts of notoginsenoside R1 and 4 to 10 parts of cordyceps polysaccharide. The preparation method is simple, the raw materials are wide in source, and the prepared composition has a very good anti-tumor effect, particularly has very good inhibition and treatment effects on thyroid cancer, is safe and free of side effects, can be used as raw materials of dietary therapy products, health-care foods and medicines, and has a wide application prospect.

The invention relates to a group of high-activity glycosyl transferases responsible for sugar chain extension and an application of the glycosyl transferases. Specifically, the invention provides glycosyl transferase and a derivative polypeptide thereof, which can efficiently catalyze the reaction of extending sugar chains on the first glycosyl at the C-20 site and the first glycosyl at the C-6 site of a tetracyclic triterpenoid substrate. The ginsenoside products such asginsenoside Rb1, the ginsenoside Rb3, the ginsenoside DMGG, the ginsenoside DMGX, the gynostemma pentaphyllum saponin LXXV, the gynostemma pentaphyllum saponin XVII, the gynostemma pentaphyllum saponin XIII, gynostemma pentaphyllum saponin IX, notoginsenoside U and the notoginsenoside R1, notoginsenoside R2, notoginsenoside R3, 3-O-beta-(D-xylopyranosyl)-beta-(D-glucopyranosyl)-CK, 20-O-glucosyl ginsenoside Rf, Rd-C20-O-Rha, ginsenoside Rg2, and ginsenoside Re and the like can be obtained. The glycosyl transferase disclosed by the invention can also be applied to construction of artificially synthesized ginsenoside and a plurality of new ginsenosides and derivatives thereof.

The present invention relates to a pharmaceutical composition for preventing or treating Gleevec-resistant leukemia, containing, as an active ingredient, ginsenoside F1 or Rg3 which exhibits a preventive or therapeutic effect on Gleevec-resistant leukemia through enhancing cell killing activity of NK cells; a method for treating Gleevec-resistant leukemia comprising a step of administering the pharmaceutical composition; and a food composition for preventing or ameliorating Gleevec-resistant leukemia. Since the pharmaceutical composition of the present invention can effectively treat leukemia that exhibits resistance to conventional Gleevec, the pharmaceutical composition can be widely used for effective leukemia treatment.

The invention relates to a method for preparing rare ginsenoside Rg2. According to the method, Cellulosimicrobium sp.21 serves as fermented culture biotransformation total saponins of panax ginseng. By means of the method, the high-quality rare ginsenoside Rg2 can be efficiently prepared.

The invention discloses a composition, a pharmaceutical preparation and an application. The composition comprises 1-5 parts by mass of ginsenoside Rg2,10-20 parts by mass of at least one of bamboo-leaves flavones, orientoside, Isoorientin, agnoside and isovitexin, and 15-25 parts by mass of taurine or pharmaceutically acceptable salt thereof. The composition can effectively prevent and / or treat cardiovascular and cerebrovascular diseases.

Medicinal composition containing ginseng secondary glycosides, its preparation method and application. The present composition contains mainly, as active ingredients, the ginsenoside with protopanoxadiol as aglucone (ginsenoside Rg3) and the ginsenoside with protopanoxatriol as aglucone (ginsenoside Rg2 and ginsenoside Rh1). It is prepared from the ginseng genus of plants through extracting, acid hydrolyzing and using macroreticular resin to separate, purify and concentrate. It is useful in the manufacture of medicaments for treating CHD, angina pectoris, myocardial ischemia, hemorrhagic shock, heart failure, and arrhythmia.

The invention discloses a use of ginsenoside Rg1 in preparation of drugs for treating fatty liver. The invention discovers the new medicinal value of ginsenoside Rg1 and develops its application field. The ginsenoside Rg1 can effectively improve high fat diet-induced liver damage and steatosis. The ginsenoside Rg1 is further used in treatment and remission of fatty liver. The invention provides adrug for treating fatty liver. The drug is prepared only from the ginsenoside Rg1 monomer and is used for treating fatty liver. The drug has good effects of treating and improving non-alcoholic fattyliver.

The invention provides a compound of formula (I): wherein R1, R2, R3, and R4 are as defined herein, ginsenoside Rg2 of structure (II): or a combination thereof, for use in treating or preventing a condition responsive to the induction of autophagy in a brain of a mammal in need thereof.

The invention discloses a method for efficiently and rapidly preparing and separating three kinds of ginsenoside isomers Rg6, Z type and E type F4. The preparation method of a saponin mixture is as follows: ginsenoside Rg2 is used as a raw material, an acid-containing alcohol-water solution is used as a reaction system, a thermal dehydration reaction is carried out, and lead dioxide is used as a catalyst. A separation method of the saponin mixture is as follows: high-speed countercurrent chromatography is used for separation, and ethyl acetate-ethanol-water-acetic acid (volume ratio is 4:1:5:0.08) is used as a solvent system. The method for preparing a mixture of ginsenoside isomers Rg6, Z type and E type F4 has high yield, 90% or above of ginsenoside Rg2 is converted into Rg6, (Z)-F4 and (E)-F4, and utilization rate of raw materials is high; The method for separating the mixture of ginsenoside isomers Rg6, Z type and E type F4 by high speed countercurrent has high separation efficiency and good separation degree, three kinds of isomers can be effectively separated, and once separation is carried out in order to obtain three kinds of isomers, wherein each mass of the isomers is 100mg or above.

The invention provides a composition for improving kidney dysfunction and belongs to the technical field of ginseng deep-processing. The composition comprises, by weight, 2-6 parts of ginsenoside Rg2,1-5 parts of ginsenoside Rg5 and 1-3 parts of ginsenoside Rk1. The composition participates in slowing down the progress of chronic kidney interstitial fibrosis by inhibiting HK-2 phenotypic differentiation so as to improve chronic kidney dysfunction. It is verified that the composition can remarkably improve kidney functions of patients at 2-3 stages of chronic kidney dysfunction CKD.

The invention relates to the field of natural medicine, in particular to a method for preparing C20 position dehydroxylation dammarane type rare ginsenoside and aglycone thereof. The method for preparing the C20 position dehydroxylation dammarane type rare ginsenoside and the aglycone thereof is achieved by combining multiple means of semi-synthesis preparation, chromatogram separation and purification and the like. The method is characterized in that ginsenoside Rg2, Rh1, Rg3, Rs3 and Rh2, protopanoxadiol and protopanaxatriol are used as raw materials, one-step dehydration reaction is performed under the acidic condition, C20 position hydroxyl is removed to generate double bond isomerous series C20 position dehydroxylation dammarane type rare ginsenoside and the aglycone thereof, a liquid phase is prepared to enrich a target compound, and the target compound is concentrated and freeze-dried to obtain the C20 position dehydroxylation dammarane type rare ginsenoside and the aglycone thereof. According to the method, raw materials are easy to obtain, the reaction steps are simple, and the preparation cost is low.